Close Menu
NEW YORK (GenomeWeb News) – Helicos BioSciences today said that it has signed a definitive agreement with certain investors to raise gross proceeds of around $18.6 million through a private placement of the firm’s shares.
 
The Cambridge, Mass.-based sequencing technology firm said that net proceeds from the offering will be roughly $17.9 million, which it intends to use for working capital and general corporate purposes.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.